Kiniksa Pharmaceuticals International PLC KNSA
$79.03 $0.56 (0.71%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
KNSA Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Kiniksa Pharmaceuticals International PLC is classified as halal.
HALAL
Report Source: undefined Quarter Report
Kiniksa Pharmaceuticals International PLC. Stock Analysis KNSA
United States Health Care Mid Cap Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Kiniksa Pharmaceuticals International PLC (KNSA) Chart
Financial Metrics & Statements of Kiniksa Pharmaceuticals International PLC (KNSA)
FAQ's for Kiniksa Pharmaceuticals International PLC (KNSA)
- As of August 2026, Kiniksa Pharmaceuticals International PLC KNSA is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kiniksa Pharmaceuticals International PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kiniksa Pharmaceuticals International PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kiniksa Pharmaceuticals International PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kiniksa Pharmaceuticals International PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kiniksa Pharmaceuticals International PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to Kiniksa Pharmaceuticals International PLC (KNSA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
